DE GIGLIO, ANDREA
DE GIGLIO, ANDREA
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Ricercatori a tempo determinato
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable
2019 Cortellini A.; Bersanelli M.; Buti S.; Cannita K.; Santini D.; Perrone F.; Giusti R.; Tiseo M.; Michiara M.; Di Marino P.; Tinari N.; De Tursi M.; Zoratto F.; Veltri E.; Marconcini R.; Malorgio F.; Russano M.; Anesi C.; Zeppola T.; Filetti M.; Marchetti P.; Botticelli A.; Antonini Cappellini G.C.; De Galitiis F.; Vitale M.G.; Rastelli F.; Pergolesi F.; Berardi R.; Rinaldi S.; Tudini M.; Silva R.R.; Pireddu A.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Iacono D.; Gelibter A.; Occhipinti M.A.; Parisi A.; Porzio G.; Fargnoli M.C.; Ascierto P.A.; Ficorella C.; Natoli C.
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
2018 Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R.
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances
2021 Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G.
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020 Cortellini A.; Bersanelli M.; Santini D.; Buti S.; Tiseo M.; Cannita K.; Perrone F.; Giusti R.; De Tursi M.; Zoratto F.; Marconcini R.; Russano M.; Zeppola T.; Anesi C.; Filetti M.; Marchetti P.; Botticelli A.; Gelibter A.; De Galitiis F.; Vitale M.G.; Rastelli F.; Tudini M.; Silva R.R.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Migliorino M.R.; Mallardo D.; Vanella V.; Mosillo C.; Bracarda S.; Rinaldi S.; Berardi R.; Natoli C.; Ficorella C.; Porzio G.; Ascierto P.A.
Antibody–drug conjugates for lung cancer in the era of personalized oncology
2021 Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R.; Pirro M.
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach
2021 De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A.
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies
2019 de Giglio A.; Nuvola G.; Gustavo Dall'Olio F.
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities
2022 De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R.
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
2020 de Giglio A.; Nuvola G.; Baldini C.
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
2020 Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Crino L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5)
2020 Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaffar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R.
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078))
2021 Banna G.L.; Cortellini A.; Cortinovis D.L.; Tiseo M.; Aerts J.G.J.V.; Barbieri F.; Giusti R.; Bria E.; Grossi F.; Pizzutilo P.; Berardi R.; Morabito A.; Genova C.; Mazzoni F.; Di Noia V.; Signorelli D.; Gelibter A.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Gori S.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Marco R.; Cantini L.; Nigro O.; D'Argento E.; Buti S.; Minuti G.; Landi L.; Guaitoli G.; Lo Russo G.; De Toma A.; Donisi C.; Friedlaender A.; De Giglio A.; Metro G.; Porzio G.; Ficorella C.; Addeo A.
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation
2018 Baglivo S.; Ricciuti B.; Ludovini V.; Metro G.; Siggillino A.; De Giglio A.; Chiari R.
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient
2016 Ricciuti B.; Leonardi G.C.; Ravaioli N.; De Giglio A.; Brambilla M.; Prosperi E.; Ribacchi F.; Meacci M.; Crino L.; Maiettini D.; Chiari R.; Metro G.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
2022 Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Lobefaro R.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar-Nana F.; Ponce S.; Dal Maso A.; Spotti M.; Mielgo-Rubio X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Planchard D.; Mezquita L.
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?
2018 De Giglio A.; Porreca R.; Brambilla M.; Metro G.; Prosperi E.; Bellezza G.; Pirro M.; Chiari R.; Ricciuti B.
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
2022 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors
2020 Tateo V.; Manuzzi L.; De Giglio A.; Parisi C.; Lamberti G.; Campana D.; Pantaleo M.A.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable | Cortellini A.; Bersanelli M.; Buti S.; Cannita K.; Santini D.; Perrone F.; Giusti R.; Tiseo M.; M...ichiara M.; Di Marino P.; Tinari N.; De Tursi M.; Zoratto F.; Veltri E.; Marconcini R.; Malorgio F.; Russano M.; Anesi C.; Zeppola T.; Filetti M.; Marchetti P.; Botticelli A.; Antonini Cappellini G.C.; De Galitiis F.; Vitale M.G.; Rastelli F.; Pergolesi F.; Berardi R.; Rinaldi S.; Tudini M.; Silva R.R.; Pireddu A.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Iacono D.; Gelibter A.; Occhipinti M.A.; Parisi A.; Porzio G.; Fargnoli M.C.; Ascierto P.A.; Ficorella C.; Natoli C. | 2019-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | - |
| Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience | Ricciuti B.; Baglivo S.; De Giglio A.; Chiari R. | 2018-01-01 | THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | - | 1.01 Articolo in rivista | - |
| An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances | Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G. | 2021-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | pharmaceuticals-14-00316.pdf |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events | Cortellini A.; Bersanelli M.; Santini D.; Buti S.; Tiseo M.; Cannita K.; Perrone F.; Giusti R.; D...e Tursi M.; Zoratto F.; Marconcini R.; Russano M.; Zeppola T.; Anesi C.; Filetti M.; Marchetti P.; Botticelli A.; Gelibter A.; De Galitiis F.; Vitale M.G.; Rastelli F.; Tudini M.; Silva R.R.; Atzori F.; Chiari R.; Ricciuti B.; De Giglio A.; Migliorino M.R.; Mallardo D.; Vanella V.; Mosillo C.; Bracarda S.; Rinaldi S.; Berardi R.; Natoli C.; Ficorella C.; Porzio G.; Ascierto P.A. | 2020-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Antibody–drug conjugates for lung cancer in the era of personalized oncology | Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R....; Pirro M. | 2021-01-01 | SEMINARS IN CANCER BIOLOGY | - | 1.01 Articolo in rivista | - |
| Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach | De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies | de Giglio A.; Nuvola G.; Gustavo Dall'Olio F. | 2019-01-01 | TRANSLATIONAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities | De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R. | 2022-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
| Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics | de Giglio A.; Nuvola G.; Baldini C. | 2020-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer | Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Cri...no L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R. | 2020-01-01 | CLINICAL & TRANSLATIONAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience | Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppion...i E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A. | 2020-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) | Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaff...ar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R. | 2020-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)) | Banna G.L.; Cortellini A.; Cortinovis D.L.; Tiseo M.; Aerts J.G.J.V.; Barbieri F.; Giusti R.; Bri...a E.; Grossi F.; Pizzutilo P.; Berardi R.; Morabito A.; Genova C.; Mazzoni F.; Di Noia V.; Signorelli D.; Gelibter A.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Gori S.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Marco R.; Cantini L.; Nigro O.; D'Argento E.; Buti S.; Minuti G.; Landi L.; Guaitoli G.; Lo Russo G.; De Toma A.; Donisi C.; Friedlaender A.; De Giglio A.; Metro G.; Porzio G.; Ficorella C.; Addeo A. | 2021-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | - |
| Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation | Baglivo S.; Ricciuti B.; Ludovini V.; Metro G.; Siggillino A.; De Giglio A.; Chiari R. | 2018-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient | Ricciuti B.; Leonardi G.C.; Ravaioli N.; De Giglio A.; Brambilla M.; Prosperi E.; Ribacchi F.; Me...acci M.; Crino L.; Maiettini D.; Chiari R.; Metro G. | 2016-01-01 | JOURNAL OF BREAST CANCER | - | 1.01 Articolo in rivista | - |
| Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations | Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Lobefaro R.; Lopez-Castro R.; Bosch-B...arrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar-Nana F.; Ponce S.; Dal Maso A.; Spotti M.; Mielgo-Rubio X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Planchard D.; Mezquita L. | 2022-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? | De Giglio A.; Porreca R.; Brambilla M.; Metro G.; Prosperi E.; Bellezza G.; Pirro M.; Chiari R.; ...Ricciuti B. | 2018-01-01 | THROMBOSIS RESEARCH | - | 1.01 Articolo in rivista | - |
| Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Franc...esca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | - |
| Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors | Tateo V.; Manuzzi L.; De Giglio A.; Parisi C.; Lamberti G.; Campana D.; Pantaleo M.A. | 2020-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-21-09056.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavo...lari S.; Di Marco M.; Palloni A.; Brandi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | articolo 2022 Immunotherapy in Pancreatic Cancer Why Do We Keep Failing A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.pdf |